Novartis Zomaril NDA Filing Awaits More Data On QTc Prolongation
Novartis is conducting additional trials to determine whether the antipsychotic iloperidone has a dose-dependant QTc prolongation side effect before it files an NDA for the agent.
Novartis is conducting additional trials to determine whether the antipsychotic iloperidone has a dose-dependant QTc prolongation side effect before it files an NDA for the agent.